Cedric Hupperetz, a scientist in the Bacteriology Research and Development division, shares his journey and current role in optimizing immunoassays for vaccine efficacy. He discusses his educational background, his passion for health sciences, and his specialized work with the Multiplexed Opsonophagocytic Assay. Cedric provides insights into the challenges of vaccine development, the clinical trial process, and the collaborative efforts of his dedicated team.
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
